Laurence Skillern

A Randomised, Double-Blinded, Placebo-Controlled Study of the Phosphodiesterase Type 5 Inhibitor Sildenafil for the Treatment of Preeclampsia

Rebekah A. Samangaya, Gary Mires, Andrew Shennan et al. · Hypertension in Pregnancy · 2009 · 160 citations

Medicine, Pharmacology, Pharmacotherapy +17

A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause

Graeme L. Fraser, Samuel Lederman, Arthur Waldbaum et al. · Menopause The Journal of The North American Menopause Society · 2020 · 118 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA)

Nanette Santoro, Arthur Waldbaum, Samuel Lederman et al. · Menopause The Journal of The North American Menopause Society · 2020 · 67 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Effects of a phosphodiesterase-5 (PDE5) inhibitor on endothelium-dependent relaxation of myometrial small arteries

Mark Wareing, Jenny Myers, Maureen O’Hara et al. · American Journal of Obstetrics and Gynecology · 2004 · 60 citations

Medicine, Pharmacology, Molecular Pharmacology +9

Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study

Thomas D’Hooghe, Takao Fukaya, Yutaka Osuga et al. · Human Reproduction · 2019 · 43 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17